Deciphera Pharmaceuticals Inc’s filing revealed that its Chief Financial Officer Kelly Thomas Patrick unloaded Company’s shares for reported $47009.0 on Feb 16 ’24. In the deal valued at $15.62 per share,3,010 shares were sold. As a result of this transaction, Kelly Thomas Patrick now holds 80,350 shares worth roughly $1.26 million.
Then, Sherman Matthew L sold 2,615 shares, generating $40,840 in total proceeds. Upon selling the shares at $15.62, the EVP & Chief Medical Officer now owns 108,739 shares.
Before that, Pitman Jama sold 2,267 shares. Deciphera Pharmaceuticals Inc shares valued at $35,405 were divested by the SVP, Chief Development Officer at a price of $15.62 per share. As a result of the transaction, Pitman Jama now holds 68,031 shares, worth roughly $1.06 million.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in late October from “a Neutral” to “an Overweight”. Stifel also remained covering DCPH and has increased its forecast on August 10, 2023 with a “Buy” recommendation from previously “Hold” rating. Guggenheim revised its rating on January 04, 2023. It rated DCPH as “a Buy” which previously was an “a Neutral”.
Price Performance Review of DCPH
On Tuesday, Deciphera Pharmaceuticals Inc [NASDAQ:DCPH] saw its stock jump 4.20% to $15.64. Over the last five days, the stock has gained 2.96%. Deciphera Pharmaceuticals Inc shares have fallen nearly -3.04% since the year began. Nevertheless, the stocks have risen 4.62% over the past one year. While a 52-week high of $17.73 was reached on 03/01/24, a 52-week low of $9.90 was recorded on 01/18/24. SMA at 50 days reached $15.59, while 200 days put it at $14.02. A total of 0.37 million shares were traded, compared to the trading of 0.37 million shares in the previous session.
Levels Of Support And Resistance For DCPH Stock
The 24-hour chart illustrates a support level at 15.16, which if violated will result in even more drops to 14.67. On the upside, there is a resistance level at 15.91. A further resistance level may holdings at 16.17. The Relative Strength Index (RSI) on the 14-day chart is 51.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 36.30%. Stochastics %K at 43.21% indicates the stock is a holding.
How much short interest is there in Deciphera Pharmaceuticals Inc?
A steep rise in short interest was recorded in Deciphera Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 0.14 million shares to a total of 5.65 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 5.51 million shares. There was a rise of 2.48%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 9.32% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.46.
The most recent change occurred on August 29, 2022 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
